Syquant Capital Sas Buys Shares of 126,300 Hologic, Inc. $HOLX

Syquant Capital Sas purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 126,300 shares of the medical equipment provider’s stock, valued at approximately $9,408,000. Hologic accounts for 1.2% of Syquant Capital Sas’ investment portfolio, making the stock its 12th biggest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Hologic by 10.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after acquiring an additional 3,520 shares during the period. Empowered Funds LLC boosted its position in Hologic by 27.7% during the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock worth $1,081,000 after acquiring an additional 3,790 shares during the period. MAI Capital Management grew its stake in shares of Hologic by 121.4% in the second quarter. MAI Capital Management now owns 651 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 357 shares in the last quarter. Prudential Financial Inc. increased its holdings in shares of Hologic by 5.2% during the second quarter. Prudential Financial Inc. now owns 129,386 shares of the medical equipment provider’s stock valued at $8,431,000 after purchasing an additional 6,431 shares during the period. Finally, XTX Topco Ltd raised its stake in shares of Hologic by 11.4% during the second quarter. XTX Topco Ltd now owns 14,505 shares of the medical equipment provider’s stock valued at $945,000 after purchasing an additional 1,490 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on HOLX shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Evercore lowered shares of Hologic from an “outperform” rating to an “in-line” rating and lowered their price objective for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Two research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Trading Up 0.2%

Shares of HOLX stock opened at $75.69 on Friday. The stock has a 50-day simple moving average of $75.21 and a 200 day simple moving average of $73.18. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The stock has a market capitalization of $16.90 billion, a P/E ratio of 31.54, a P/E/G ratio of 2.24 and a beta of 0.73. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $0.87 earnings per share. Hologic’s revenue was up 2.5% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.